Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.

Details

Language :

English

ISSN :

15560864

Volume :

18

Issue :

8

Database :

Complementary Index

Journal :

Journal of Thoracic Oncology

Publication Type :

Academic Journal

Accession number :

165040717

Full Text :

https://doi.org/10.1016/j.jtho.2023.04.020